Physician profile
Sandra R Rozar
NPI 1659350940
$328.32
in general payments reported to CMS, 2019-2025
10 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.88 · 2020: $12.91 · 2021: $22.29 · 2024: $107 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $279.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $96.43 | 2025 | Miebo, Xiidra |
| Alcon Vision LLC | $40.87 | 2021-2024 | Total30 |
| Harrow Eye, LLC | $29.28 | 2024 | Vevye |
| Dompe US, INC. | $28.05 | 2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $26.79 | 2019-2020 | |
| Oyster Point Pharma, INC. | $24.15 | 2025 | Tyrvaya |
| Regeneron Healthcare Solutions, INC. | $24.02 | 2024 | Eylea Hd |
| Tarsus Pharmaceuticals, INC. | $23.79 | 2025 | Xdemvy |
| Coopervision INC. | $20.86 | 2024 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $14.08 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Rozar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.